Scientific Reports · 2018 · 24 citations · 26 references
MedicineCancer BiologyOncologyApoptosisCancer PharmacologyMolecular OncologyApoptosis In CancerApoptosis ModulationApoptosis PharmacologyApoptotic SignalingApoptosis TargetingMyc In LymphomaParp InhibitionPro-apoptotic EffectorsPro-apoptotic ModulationPro-apoptotic ProteinsProapoptotic Protein SignalingTraditional Herbal Medicine
Angelica gigas Nakai (AGN) is an oriental traditional medicine to treat anemia, dysmenorrhea, and migraine. However, its anti-lymphoma effect is yet to be tested. Here, we demonstrated that AGN and its major component decursin target Myc to suppress lymphomagenesis in vitro and in vivo. AGN inhibited cell viability in multiple B lymphoma cells, while sparing normal splenocytes and bone marrow cells. Increased cleaved PARP level and caspase 3/7 activity and the repression of survival-promoting AKT/mTOR and MAPK pathways downstream of BCR, were responsible for the pro-apoptotic effects of AGN. We found that Myc, a prominent downstream target of these signaling pathways, contributes to AGN-induced cell death. Moreover, co-treatment with AGN and a Myc inhibitor, JQ1 or 10058-F4 yielded synergistic cytotoxic activities against cancer cells with markedly reduced Myc expression. AGN downregulated Myc expression and suppressed tumorigenesis in Eμ-myc transgenic mice. The proapoptotic activities of AGN were recapitulated by decursin, indicating that the anti-tumor effect of AGN was mainly caused by decursin. These findings suggest that AGN and decursin possess potent anti-lymphoma activity, and combination therapies with AGN/decursin and a Myc inhibitor to target Myc more efficiently could be a valuable avenue to explore in the treatment of B-cell lymphoma.
26
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
Ash A. Alizadeh, Michael B. Eisen, R. Eric Davis et al. · Nature · 2000 · 10K citations
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice
Jerry M. Adams, A. W. Harris, Carl A. Pinkert et al. · Nature · 1985 · 1.8K citations
Shaoying Li, Ken H. Young, L. Jeffrey Medeiros · Pathology · 2017 · 630 citations
Medicine, Dermatology, Oncology +11
BET inhibitor resistance emerges from leukaemia stem cells
Chun Yew Fong, Omer Gilan, Enid Y.N. Lam et al. · Nature · 2015 · 548 citations · Full text
Medicine, Cancer Biology, Oncology +14